TDMS Study 55301-05 Pathology Tables
NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 Facility: TSI Mason Research Chemical CAS #: 110-86-1 Lock Date: 12/15/94 Cage Range: All Reasons For Removal: All Removal Date Range: All Treatment Groups: Include All a Number of animals examined microscopically at site and number of animals with lesion Page 1 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 50 50 50 50 Early Deaths Natural Death 15 5 14 22 Moribund Sacrifice 3 8 7 2 Survivors Terminal Sacrifice 32 37 29 26 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Colon (50) (50) (50) (50) Hyperplasia, Lymphoid 1 (2%) Parasite Metazoan 3 (6%) 3 (6%) 3 (6%) 1 (2%) Intestine Large, Rectum (50) (50) (50) (50) Parasite Metazoan 1 (2%) 2 (4%) 1 (2%) 2 (4%) Intestine Large, Cecum (50) (50) (50) (50) Inflammation, Chronic 1 (2%) Inflammation, Chronic Active 1 (2%) Parasite Metazoan 1 (2%) Ulcer 1 (2%) Intestine Small, Duodenum (50) (50) (50) (50) Ectopic Pancreas 1 (2%) Inflammation, Chronic Active 1 (2%) Intestine Small, Ileum (50) (49) (50) (50) Hyperplasia, Lymphoid 3 (6%) 2 (4%) 2 (4%) 5 (10%) Inflammation, Chronic Active 1 (2%) Liver (50) (50) (50) (50) Angiectasis 2 (4%) 2 (4%) 3 (6%) 2 (4%) Basophilic Focus 38 (76%) 28 (56%) 11 (22%) Clear Cell Focus 4 (8%) 9 (18%) 11 (22%) 16 (32%) Congestion 4 (8%) 1 (2%) 3 (6%) 2 (4%) Developmental Malformation 1 (2%) 2 (4%) 1 (2%) Eosinophilic Focus 19 (38%) 24 (48%) 22 (44%) 15 (30%) Fibrosis 1 (2%) 1 (2%) Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 2 (4%) Hemorrhage 1 (2%) 1 (2%) Hepatodiaphragmatic Nodule 9 (18%) 8 (16%) 3 (6%) 3 (6%) Inflammation, Chronic Active 9 (18%) 1 (2%) 2 (4%) 4 (8%) Mitotic Alteration 1 (2%) 1 (2%) Mixed Cell Focus 2 (4%) 4 (8%) 1 (2%) 5 (10%) Necrosis 6 (12%) 1 (2%) 1 (2%) Pigmentation 6 (12%) 2 (4%) 6 (12%) 17 (34%) Tension Lipidosis 3 (6%) 1 (2%) Vacuolization Cytoplasmic 10 (20%) 7 (14%) 9 (18%) 18 (36%) a Number of animals examined microscopically at site and number of animals with lesion Page 2 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - CONT Bile Duct, Hyperplasia 20 (40%) 29 (58%) 34 (68%) 29 (58%) Capsule, Inflammation, Chronic 2 (4%) Centrilobular, Cytomegaly 1 (2%) 4 (8%) 20 (40%) Centrilobular, Degeneration 1 (2%) 2 (4%) 2 (4%) 7 (14%) Centrilobular, Necrosis 1 (2%) 2 (4%) 1 (2%) Mesentery (9) (11) (7) (12) Ectopic Spleen 1 (14%) Inflammation 1 (8%) Fat, Necrosis 8 (89%) 9 (82%) 6 (86%) 11 (92%) Oral Mucosa (2) (1) (2) Pharyngeal, Hyperplasia 1 (50%) Pharyngeal, Inflammation, Acute 1 (100%) Pancreas (49) (50) (50) (50) Atrophy 22 (45%) 14 (28%) 13 (26%) 14 (28%) Cytoplasmic Alteration 1 (2%) Ectopic Liver 2 (4%) 2 (4%) 3 (6%) Hyperplasia 3 (6%) 2 (4%) Inflammation, Chronic 1 (2%) 2 (4%) Salivary Glands (50) (50) (50) (50) Atrophy 2 (4%) 3 (6%) 1 (2%) Cytoplasmic Alteration 1 (2%) 1 (2%) Inflammation, Chronic 2 (4%) Stomach, Forestomach (50) (50) (50) (50) Fibrosis 1 (2%) Hyperkeratosis 1 (2%) Inflammation, Acute 1 (2%) 1 (2%) Inflammation, Chronic 1 (2%) 1 (2%) Inflammation, Chronic Active 2 (4%) 1 (2%) 2 (4%) 1 (2%) Ulcer 3 (6%) 3 (6%) 4 (8%) 4 (8%) Epithelium, Hyperplasia, Squamous 2 (4%) 2 (4%) 2 (4%) 1 (2%) Stomach, Glandular (50) (50) (50) (50) Erosion 6 (12%) 9 (18%) 9 (18%) 7 (14%) Inflammation, Chronic 1 (2%) Inflammation, Chronic Active 1 (2%) Mineralization 2 (4%) Ulcer 1 (2%) 1 (2%) 3 (6%) Tongue (1) (2) Epithelium, Hyperplasia 1 (100%) 1 (50%) ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (49) (50) (50) (50) Cardiomyopathy 42 (86%) 43 (86%) 43 (86%) 36 (72%) Inflammation, Chronic Active 1 (2%) Mineralization 1 (2%) Thrombosis 2 (4%) 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 3 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (50) (50) (50) Accessory Adrenal Cortical Nodule 1 (2%) Atrophy 1 (2%) Congestion 1 (2%) 1 (2%) Cyst 1 (2%) 1 (2%) Hematopoietic Cell Proliferation 1 (2%) Hemorrhage 1 (2%) Hyperplasia 11 (22%) 12 (24%) 9 (18%) 6 (12%) Vacuolization Cytoplasmic 6 (12%) 8 (16%) 6 (12%) 3 (6%) Adrenal Medulla (50) (50) (50) (49) Hyperplasia 5 (10%) 7 (14%) 8 (16%) 2 (4%) Necrosis 1 (2%) Islets, Pancreatic (49) (50) (50) (50) Hyperplasia 1 (2%) 1 (2%) Parathyroid Gland (48) (50) (48) (50) Hyperplasia 1 (2%) Pituitary Gland (49) (50) (50) (50) Pigmentation 1 (2%) Pars Distalis, Angiectasis 11 (22%) 9 (18%) 12 (24%) 4 (8%) Pars Distalis, Cyst 16 (33%) 18 (36%) 20 (40%) 8 (16%) Pars Distalis, Ectasia 1 (2%) Pars Distalis, Hemorrhage 1 (2%) Pars Distalis, Hyperplasia 22 (45%) 29 (58%) 21 (42%) 18 (36%) Pars Intermedia, Hyperplasia 1 (2%) Thyroid Gland (50) (50) (50) (50) Ultimobranchial Cyst 3 (6%) 1 (2%) C-Cell, Hyperplasia 16 (32%) 17 (34%) 13 (26%) 10 (20%) Follicular Cell, Hyperplasia 1 (2%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Clitoral Gland (47) (48) (50) (49) Hyperplasia 1 (2%) 2 (4%) 1 (2%) 2 (4%) Inflammation, Acute 1 (2%) 2 (4%) Inflammation, Chronic 3 (6%) 1 (2%) 5 (10%) 2 (4%) Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (4%) 1 (2%) Vacuolization Cytoplasmic 1 (2%) Bilateral, Inflammation, Acute 1 (2%) Duct, Ectasia 3 (6%) 5 (10%) 4 (8%) 2 (4%) a Number of animals examined microscopically at site and number of animals with lesion Page 4 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM - CONT Ovary (50) (50) (50) (50) Congestion 1 (2%) Cyst 3 (6%) 7 (14%) 4 (8%) 2 (4%) Hyperplasia 1 (2%) Inflammation, Chronic 1 (2%) 1 (2%) Pigmentation 1 (2%) Bilateral, Cyst 1 (2%) 2 (4%) Uterus (50) (50) (50) (50) Angiectasis 1 (2%) Cyst 1 (2%) 1 (2%) Developmental Malformation 1 (2%) Dilatation 1 (2%) 1 (2%) 2 (4%) Hemorrhage 1 (2%) 1 (2%) Hyperplasia 1 (2%) Hyperplasia, Cystic 6 (12%) 5 (10%) 7 (14%) Inflammation, Acute 1 (2%) Inflammation, Chronic 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) Metaplasia, Squamous 1 (2%) Necrosis 1 (2%) 1 (2%) Cervix, Hypertrophy 1 (2%) Cervix, Inflammation, Chronic 1 (2%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Depletion Cellular 1 (2%) 2 (4%) 2 (4%) Fibrosis 1 (2%) 1 (2%) Hyperplasia 3 (6%) 4 (8%) 1 (2%) Hyperplasia, Reticulum Cell 1 (2%) Necrosis 1 (2%) Erythroid Cell, Hyperplasia 1 (2%) Myeloid Cell, Hyperplasia 1 (2%) Lymph Node (7) (9) (15) (19) Iliac, Congestion 2 (29%) Iliac, Ectasia 2 (11%) Mediastinal, Congestion 3 (43%) 1 (11%) 4 (27%) 1 (5%) Mediastinal, Hyperplasia, Lymphoid 1 (7%) Mediastinal, Pigmentation 1 (14%) 1 (5%) Pancreatic, Congestion 1 (7%) Pancreatic, Pigmentation 1 (11%) Renal, Congestion 1 (14%) 1 (11%) 1 (7%) Renal, Ectasia 1 (11%) 1 (5%) Renal, Hyperplasia, Lymphoid 1 (5%) Lymph Node, Mandibular (49) (50) (50) (50) Atrophy 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 5 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - CONT Congestion 1 (2%) 1 (2%) Ectasia 3 (6%) 4 (8%) 9 (18%) 2 (4%) Edema 1 (2%) Hyperplasia, Lymphoid 1 (2%) 1 (2%) 1 (2%) Hyperplasia, Plasma Cell 1 (2%) Infiltration Cellular, Plasma Cell 1 (2%) Necrosis 1 (2%) Lymph Node, Mesenteric (49) (50) (50) (50) Congestion 2 (4%) 3 (6%) Ectasia 4 (8%) Hemorrhage 1 (2%) Hyperplasia, Lymphoid 2 (4%) 2 (4%) Inflammation, Acute 1 (2%) Inflammation, Chronic 1 (2%) Spleen (50) (50) (50) (50) Atrophy 1 (2%) Congestion 1 (2%) 2 (4%) Fibrosis 2 (4%) 3 (6%) 3 (6%) 4 (8%) Hematopoietic Cell Proliferation 2 (4%) 4 (8%) 2 (4%) Hemorrhage 2 (4%) Metaplasia, Osseous 1 (2%) Necrosis 1 (2%) 2 (4%) 1 (2%) Pigmentation 1 (2%) Capsule, Inflammation, Chronic 1 (2%) Thymus (50) (50) (50) (50) Congestion 1 (2%) Cyst 1 (2%) Ectopic Parathyroid Gland 2 (4%) 1 (2%) 1 (2%) 2 (4%) Fibrosis 1 (2%) Inflammation, Acute 1 (2%) Inflammation, Chronic 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (50) (50) (50) (50) Galactocele 3 (6%) 5 (10%) 1 (2%) Hyperplasia 5 (10%) 2 (4%) 6 (12%) 5 (10%) Inflammation, Chronic Active 1 (2%) Duct, Dilatation 13 (26%) 9 (18%) 13 (26%) 13 (26%) Skin (50) (50) (50) (50) Hyperkeratosis 2 (4%) Hyperplasia, Squamous 2 (4%) 1 (2%) 1 (2%) 1 (2%) Inflammation, Acute 1 (2%) 1 (2%) Inflammation, Chronic 1 (2%) Inflammation, Chronic Active 2 (4%) 1 (2%) 1 (2%) Subcutaneous Tissue, Fibrosis 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 6 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Osteopetrosis 9 (18%) 12 (24%) 10 (20%) 5 (10%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (50) (50) Hemorrhage 1 (2%) 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Congestion 1 (2%) Hemorrhage 1 (2%) Infiltration Cellular, Histiocyte 13 (26%) 10 (20%) 9 (18%) 11 (22%) Inflammation, Chronic 9 (18%) 8 (16%) 6 (12%) 8 (16%) Bronchiole, Alveolus, Hyperplasia 1 (2%) Nose (50) (50) (50) (50) Congestion 1 (2%) Cyst 1 (2%) 1 (2%) Hemorrhage 1 (2%) Inflammation, Chronic 2 (4%) 3 (6%) Inflammation, Chronic Active 15 (30%) 15 (30%) 16 (32%) 19 (38%) Nasolacrimal Duct, Cyst 2 (4%) Nasolacrimal Duct, Inflammation, Chronic Active 1 (2%) 1 (2%) Respiratory Epithelium, Hyperplasia 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (1) (2) Hemorrhage 1 (100%) 2 (100%) Harderian Gland (1) Inflammation, Chronic 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (50) (50) (50) Accumulation, Hyaline Droplet 1 (2%) Congestion 2 (4%) 1 (2%) Cyst 1 (2%) Hydronephrosis 2 (4%) a Number of animals examined microscopically at site and number of animals with lesion Page 7 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS FEMALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ URINARY SYSTEM - CONT Inflammation, Acute 1 (2%) Mineralization 3 (6%) 4 (8%) 6 (12%) Nephropathy 41 (82%) 42 (84%) 35 (70%) 37 (74%) Pigmentation 2 (4%) 1 (2%) Renal Tubule, Hyperplasia 1 (2%) Urinary Bladder (50) (50) (50) (50) Hemorrhage 1 (2%) Inflammation, Chronic 3 (6%) 1 (2%) 2 (4%) a Number of animals examined microscopically at site and number of animals with lesion Page 8 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ DISPOSITION SUMMARY Animals Initially In Study 50 50 50 50 Early Deaths Moribund Sacrifice 11 13 15 10 Natural Death 14 17 10 24 Survivors Terminal Sacrifice 25 20 25 16 Animals Examined Microscopically 50 50 50 50 ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM Intestine Large, Colon (50) (48) (50) (49) Hyperplasia, Lymphoid 1 (2%) Inflammation, Acute 1 (2%) Inflammation, Chronic 1 (2%) Parasite Metazoan 4 (8%) 4 (8%) 3 (6%) 2 (4%) Intestine Large, Rectum (50) (48) (50) (49) Edema 1 (2%) Parasite Metazoan 4 (8%) 2 (4%) 1 (2%) Intestine Large, Cecum (49) (47) (50) (49) Edema 1 (2%) Hyperplasia, Lymphoid 1 (2%) Inflammation, Acute 1 (2%) 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) Parasite Metazoan 1 (2%) 1 (2%) Ulcer 1 (2%) Intestine Small, Duodenum (50) (47) (50) (48) Ectopic Pancreas 1 (2%) Intestine Small, Jejunum (50) (47) (50) (47) Congestion 1 (2%) Intestine Small, Ileum (50) (47) (50) (47) Fibrosis 1 (2%) Hyperplasia, Lymphoid 6 (12%) 9 (19%) 3 (6%) 4 (9%) Liver (50) (49) (50) (50) Angiectasis 1 (2%) 1 (2%) 1 (2%) Basophilic Focus 12 (24%) 5 (10%) 1 (2%) Clear Cell Focus 7 (14%) 1 (2%) 7 (14%) 4 (8%) Congestion 1 (2%) Degeneration, Cystic 4 (8%) 12 (24%) 11 (22%) 3 (6%) Developmental Malformation 1 (2%) 1 (2%) Eosinophilic Focus 14 (28%) 23 (47%) 23 (46%) 13 (26%) Fibrosis 1 (2%) 1 (2%) 1 (2%) 10 (20%) Hematopoietic Cell Proliferation 2 (4%) 1 (2%) Hepatodiaphragmatic Nodule 3 (6%) 1 (2%) Mitotic Alteration 2 (4%) a Number of animals examined microscopically at site and number of animals with lesion Page 9 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ ALIMENTARY SYSTEM - CONT Mixed Cell Focus 2 (4%) 1 (2%) 3 (6%) 1 (2%) Necrosis 2 (4%) 1 (2%) 1 (2%) 2 (4%) Pigmentation 4 (8%) 11 (22%) 20 (40%) 25 (50%) Thrombosis 1 (2%) Vacuolization Cytoplasmic 4 (8%) 6 (12%) 13 (26%) 17 (34%) Bile Duct, Hyperplasia 46 (92%) 43 (88%) 44 (88%) 49 (98%) Centrilobular, Cytomegaly 4 (8%) 8 (16%) 6 (12%) Centrilobular, Degeneration 1 (2%) 3 (6%) 2 (4%) 8 (16%) Centrilobular, Necrosis 3 (6%) 5 (10%) Periportal, Fibrosis 2 (4%) 29 (58%) Mesentery (11) (14) (7) (8) Cyst 1 (9%) Hemorrhage 1 (14%) Inflammation, Acute 1 (7%) Fat, Necrosis 10 (91%) 13 (93%) 6 (86%) 8 (100%) Oral Mucosa (1) (2) Pharyngeal, Hyperplasia 1 (50%) Pancreas (50) (48) (50) (49) Atrophy 18 (36%) 15 (31%) 17 (34%) 12 (24%) Cytoplasmic Alteration 2 (4%) Hyperplasia 2 (4%) 4 (8%) 2 (4%) 3 (6%) Inflammation, Chronic 1 (2%) 3 (6%) Acinus, Hyperplasia 1 (2%) Artery, Inflammation, Acute 1 (2%) Salivary Glands (50) (50) (50) (50) Cellular Alteration 1 (2%) Inflammation, Chronic Active 1 (2%) Stomach, Forestomach (50) (49) (50) (49) Hyperkeratosis 2 (4%) Inflammation, Acute 1 (2%) 1 (2%) Inflammation, Chronic Active 2 (4%) 8 (16%) Ulcer 2 (4%) 10 (20%) 3 (6%) 4 (8%) Epithelium, Hyperplasia, Squamous 1 (2%) 7 (14%) 7 (14%) 11 (22%) Stomach, Glandular (50) (49) (50) (49) Erosion 15 (30%) 17 (35%) 12 (24%) 12 (24%) Inflammation, Acute 1 (2%) Inflammation, Chronic 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) 1 (2%) Mineralization 2 (4%) 2 (4%) 8 (16%) Necrosis 1 (2%) Ulcer 2 (4%) 5 (10%) 1 (2%) 1 (2%) Tooth (2) (1) (1) Dysplasia 1 (100%) Inflammation, Acute 1 (50%) Inflammation, Chronic Active 1 (50%) 1 (100%) ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion Page 10 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ CARDIOVASCULAR SYSTEM Heart (50) (50) (50) (50) Cardiomyopathy 45 (90%) 43 (86%) 43 (86%) 46 (92%) Mineralization 1 (2%) 3 (6%) 2 (4%) Thrombosis 2 (4%) 6 (12%) 3 (6%) 4 (8%) Coronary Artery, Inflammation, Chronic Active 1 (2%) ____________________________________________________________________________________________________________________________________ ENDOCRINE SYSTEM Adrenal Cortex (50) (49) (50) (50) Accessory Adrenal Cortical Nodule 1 (2%) 1 (2%) Congestion 1 (2%) Hyperplasia 8 (16%) 7 (14%) 7 (14%) 2 (4%) Hypertrophy 1 (2%) 2 (4%) Vacuolization Cytoplasmic 9 (18%) 5 (10%) 9 (18%) 7 (14%) Adrenal Medulla (50) (49) (50) (49) Hyperplasia 17 (34%) 22 (45%) 19 (38%) 15 (31%) Bilateral, Hyperplasia 1 (2%) 1 (2%) 1 (2%) Islets, Pancreatic (50) (48) (50) (49) Hyperplasia 5 (10%) 2 (4%) 1 (2%) 1 (2%) Parathyroid Gland (50) (50) (50) (48) Hyperplasia 1 (2%) 3 (6%) 3 (6%) Pituitary Gland (50) (50) (50) (50) Pars Distalis, Angiectasis 2 (4%) 2 (4%) 2 (4%) Pars Distalis, Cyst 2 (4%) 8 (16%) 3 (6%) 1 (2%) Pars Distalis, Degeneration 1 (2%) Pars Distalis, Ectasia 1 (2%) Pars Distalis, Hemorrhage 1 (2%) Pars Distalis, Hyperplasia 22 (44%) 16 (32%) 18 (36%) 12 (24%) Pars Distalis, Thrombosis 1 (2%) Thyroid Gland (50) (50) (50) (49) Pigmentation 1 (2%) Ultimobranchial Cyst 1 (2%) 1 (2%) 1 (2%) C-Cell, Hyperplasia 7 (14%) 5 (10%) 3 (6%) 3 (6%) Follicle, Dilatation 1 (2%) 1 (2%) 1 (2%) 2 (4%) Follicular Cell, Hyperplasia 1 (2%) 5 (10%) 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ GENERAL BODY SYSTEM None ____________________________________________________________________________________________________________________________________ a Number of animals examined microscopically at site and number of animals with lesion Page 11 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ GENITAL SYSTEM Epididymis (49) (49) (49) (48) Fibrosis 1 (2%) Inflammation, Chronic 2 (4%) Penis (1) Inflammation, Chronic Active 1 (100%) Preputial Gland (50) (47) (49) (48) Atrophy 1 (2%) Hyperplasia 4 (8%) 3 (6%) 5 (10%) 4 (8%) Inflammation, Acute 2 (4%) 2 (4%) Inflammation, Chronic 17 (34%) 25 (53%) 17 (35%) 23 (48%) Inflammation, Chronic Active 5 (10%) 14 (30%) 14 (29%) 5 (10%) Duct, Dilatation 2 (4%) 2 (4%) Prostate (50) (48) (50) (49) Hemorrhage, Chronic 1 (2%) Hyperplasia, Focal 1 (2%) 1 (2%) 4 (8%) 2 (4%) Inflammation, Acute 2 (4%) 2 (4%) 1 (2%) Inflammation, Chronic 2 (4%) 1 (2%) 4 (8%) 3 (6%) Inflammation, Chronic Active 31 (62%) 29 (60%) 24 (48%) 22 (45%) Seminal Vesicle (50) (47) (50) (48) Dilatation 1 (2%) Fibrosis 1 (2%) Inflammation, Acute 1 (2%) 1 (2%) Inflammation, Chronic 1 (2%) 1 (2%) Inflammation, Chronic Active 1 (2%) 1 (2%) 2 (4%) 1 (2%) Mineralization 1 (2%) Testes (49) (49) (49) (48) Atrophy 2 (4%) Necrosis 1 (2%) Thrombosis 1 (2%) Bilateral, Interstitial Cell, Hyperplasia 3 (6%) 2 (4%) 3 (6%) 1 (2%) Interstitial Cell, Hyperplasia 9 (18%) 6 (12%) 6 (12%) 4 (8%) ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM Bone Marrow (50) (50) (50) (50) Depletion Cellular 2 (4%) 4 (8%) 3 (6%) 1 (2%) Fibrosis 1 (2%) 1 (2%) Hemorrhage 1 (2%) Lymph Node (20) (25) (20) (23) Iliac, Hyperplasia, Lymphoid 1 (5%) 1 (4%) Iliac, Infiltration Cellular, Plasma Cell 1 (5%) Mediastinal, Congestion 5 (20%) 4 (17%) Mediastinal, Ectasia 1 (5%) Mediastinal, Hemorrhage 1 (5%) 1 (4%) 2 (10%) Mediastinal, Hyperplasia, Lymphoid 1 (4%) a Number of animals examined microscopically at site and number of animals with lesion Page 12 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ HEMATOPOIETIC SYSTEM - CONT Mediastinal, Pigmentation 1 (5%) Pancreatic, Congestion 1 (5%) 2 (9%) Pancreatic, Edema 1 (4%) Pancreatic, Hyperplasia, Lymphoid 1 (5%) Pancreatic, Inflammation, Chronic Active 1 (4%) Pancreatic, Necrosis 1 (5%) Pancreatic, Pigmentation 1 (5%) Renal, Congestion 1 (5%) 1 (5%) 3 (13%) Renal, Edema 1 (5%) Renal, Fibrosis 1 (4%) Renal, Hyperplasia, Lymphoid 2 (10%) Renal, Pigmentation 1 (5%) 4 (17%) Lymph Node, Mandibular (50) (50) (50) (50) Congestion 1 (2%) 1 (2%) Ectasia 4 (8%) 3 (6%) 2 (4%) 3 (6%) Hyperplasia, Lymphoid 1 (2%) Inflammation, Chronic Active 1 (2%) Lymph Node, Mesenteric (50) (47) (50) (48) Congestion 2 (4%) 1 (2%) Ectasia 2 (4%) 3 (6%) 2 (4%) 1 (2%) Fibrosis 2 (4%) Hemorrhage 1 (2%) 1 (2%) Inflammation, Acute 1 (2%) Necrosis 3 (6%) Spleen (49) (48) (50) (49) Atrophy 1 (2%) Congestion 1 (2%) 1 (2%) Fibrosis 14 (29%) 11 (23%) 9 (18%) 12 (24%) Hematopoietic Cell Proliferation 1 (2%) 1 (2%) 1 (2%) Hyperplasia, Focal 1 (2%) Necrosis 4 (8%) 2 (4%) 1 (2%) Pigmentation 2 (4%) Thrombosis 1 (2%) Thymus (50) (49) (48) (50) Cyst 1 (2%) Ectopic Parathyroid Gland 1 (2%) Fibrosis 1 (2%) Hemorrhage 1 (2%) 1 (2%) ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM Mammary Gland (49) (48) (50) (49) Concretion 1 (2%) Galactocele 1 (2%) Hyperplasia 1 (2%) 3 (6%) 2 (4%) 3 (6%) Duct, Dilatation 14 (29%) 16 (33%) 12 (24%) 15 (31%) a Number of animals examined microscopically at site and number of animals with lesion Page 13 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ INTEGUMENTARY SYSTEM - CONT Skin (50) (50) (50) (50) Cyst Epithelial Inclusion 2 (4%) Hyperkeratosis 1 (2%) Hyperplasia, Squamous 1 (2%) 1 (2%) Inflammation, Acute 1 (2%) Necrosis 1 (2%) Epidermis, Degeneration 1 (2%) Subcutaneous Tissue, Inflammation, Chronic Active 1 (2%) ____________________________________________________________________________________________________________________________________ MUSCULOSKELETAL SYSTEM Bone (50) (50) (50) (50) Fibrous Osteodystrophy 2 (4%) 1 (2%) 4 (8%) 6 (12%) Hyperostosis 1 (2%) Osteomalacia 1 (2%) Osteopetrosis 1 (2%) 2 (4%) ____________________________________________________________________________________________________________________________________ NERVOUS SYSTEM Brain (50) (50) (48) (50) Hemorrhage 1 (2%) Hydrocephalus 1 (2%) Inflammation, Acute 1 (2%) ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM Lung (50) (50) (50) (50) Congestion 1 (2%) 2 (4%) Hemorrhage 2 (4%) 2 (4%) Hyperplasia, Lymphoid 1 (2%) 1 (2%) Infiltration Cellular, Histiocyte 6 (12%) 4 (8%) 9 (18%) 9 (18%) Inflammation, Chronic 8 (16%) 10 (20%) 12 (24%) 9 (18%) Metaplasia, Osseous 1 (2%) Alveolar Epithelium, Hyperplasia 3 (6%) 3 (6%) Nose (50) (50) (49) (50) Cyst 1 (2%) 1 (2%) Cyst Epithelial Inclusion 1 (2%) Inflammation, Chronic 1 (2%) Inflammation, Chronic Active 26 (52%) 18 (36%) 21 (43%) 25 (50%) Polyp Inflammatory 1 (2%) Nasolacrimal Duct, Cyst 1 (2%) 1 (2%) Nasolacrimal Duct, Inflammation, Acute 1 (2%) 1 (2%) Squamous Epithelium, Nasolacrimal Duct, a Number of animals examined microscopically at site and number of animals with lesion Page 14 NTP Experiment-Test: 55301-05 INCIDENCE RATES OF NONNEOPLASTIC LESIONS BY ANATOMIC SITE (a) Report: PEIRPT03 Study Type: CHRONIC PYRIDINE Date: 10/08/97 Route: DOSED WATER Time: 11:05:00 ____________________________________________________________________________________________________________________________________ FISCHER 344 RATS MALE 0 PPM 100 PPM 200 PPM 400 PPM ____________________________________________________________________________________________________________________________________ RESPIRATORY SYSTEM - CONT Hyperplasia 1 (2%) ____________________________________________________________________________________________________________________________________ SPECIAL SENSES SYSTEM Eye (1) Atrophy 1 (100%) ____________________________________________________________________________________________________________________________________ URINARY SYSTEM Kidney (50) (48) (50) (49) Atrophy 1 (2%) Cyst 3 (6%) 3 (6%) 13 (26%) 10 (20%) Developmental Malformation 2 (4%) Hydronephrosis 3 (6%) 1 (2%) 2 (4%) Inflammation, Acute 1 (2%) Nephropathy 47 (94%) 47 (98%) 49 (98%) 49 (100%) Pigmentation 1 (2%) Artery, Inflammation, Acute 1 (2%) Artery, Inflammation, Chronic Active 1 (2%) Capsule, Hemorrhage, Chronic 1 (2%) Pelvis, Inflammation, Acute 1 (2%) Renal Tubule, Hyperplasia 1 (2%) 4 (8%) 7 (14%) Urinary Bladder (50) (47) (50) (49) Hemorrhage 1 (2%) 1 (2%) 1 (2%) Inflammation, Chronic 4 (8%) 1 (2%) 1 (2%) a Number of animals examined microscopically at site and number of animals with lesion Page 15 ------------------------------------------------------------ ---------- END OF REPORT ---------- ------------------------------------------------------------